In part 1 of this Exclusive Interview, Dr. Aaron Vinik talks with Diabetes in Control Publisher Steve Freed during the AACE 2017 convention in Austin, Texas about the current progress of INGAP and the challenges yet to be overcome.

In this week's Homerun Slides, we conclude our 12-part series with pharmacologic approaches to treating chronic kidney disease in type 2.

Future directions and potential application of metabolite profiling in type 2 diabetes: metabolomics approaches have unmasked a variety of metabolic pathways influenced by T2DM or insulin resistance, moving the field of metabolic physiology beyond a “glucocentric” viewpoint of these conditions. However, a difficulty in interpretation is that the fasting concentration of a metabolite only reflects a single moment in time, and etiology or tissue origins of any metabolite differences across comparator groups requires further validation.

Over the years we have heard that there are more than two types of diabetes. In fact we have carried articles in the past stating that Alzheimer’s is really a form of diabetes. These monikers often disappear in a short time period and are forgotten. This week we bring you …

Diabetes has long been divided into type 1 and type 2. But a third type has entered the mix — and we aren't diagnosing it correctly.

SGLT-2 inhibitors were associated with more acute renal failure reports than other diabetes medications.

New study suggests improvement in quality of life and obesity seen with liraglutide compared with placebo.

Sensor-augmented therapy can diminish hypoglycemia with the low-glucose suspend feature.

Study uses continuous glucose monitoring (CGM) systems to assess blood glucose levels during sleep.

Living with diabetes often leads me to wonder if what I’m experiencing—particularly when it’s an irritated joint or an overuse injury—is a consequence of being a regularly physically active person, getting older, or having diabetes, or some combination of those. Which one of these is causing my joint issues? Is it possible to know? I will attempt to answer these questions based on my deeper dive into the published research.